Trade

with

Celldex Therapeutics Inc
(NASDAQ: CLDX)
AdChoices
15.50
+0.09
+0.58%
After Hours :
15.60
+0.10
+0.65%

Open

15.40

Previous Close

15.41

Volume (Avg)

1.84M (1.89M)

Day's Range

15.20-15.99

52Wk Range

10.76-33.33

Market Cap.

1.39B

Dividend Rate ( Yield )

-

Beta

2.76

Shares Outstanding

89.40M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 4.11M

    • Net Income

    • -81.55M

    • Market Cap.

    • 1.39B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -3,963.92

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.76

    • Forward P/E

    • -11.83

    • Price/Sales

    • 500.00

    • Price/Book Value

    • 5.22

    • Price/Cash flow

    • -15.60

      • EBITDA

      • -77.68M

      • Return on Capital %

      • -41.87

      • Return on Equity %

      • -46.73

      • Return on Assets %

      • -41.87

      • Book Value/Share

      • 2.97

      • Shares Outstanding

      • 89.40M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 36.80

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -1.42

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 510.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -11.22

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -3,963.92

            • 39.38

            • Net Profit Margin

            • -3,963.92

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 33.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -648.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -648.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.06

              • 2.92

              • Quick Ratio

              • 11.93

              • 2.35

              • Interest Coverage

              • -1,053.89

              • 38.02

              • Leverage Ratio

              • 1.12

              • 2.21

              • Book Value/Share

              • 2.97

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -12.85

                • 217.39

                • P/E Ratio 5-Year High

                • -32.20

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.70

                • 124.82

                • Price/Sales Ratio

                • 500.00

                • 9.52

                • Price/Book Value

                • 5.22

                • 8.61

                • Price/Cash Flow Ratio

                • -15.60

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -46.73

                        (-51.20)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -41.87

                        (-33.50)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -46.69

                        (-45.40)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.01

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -81.44M
                      Operating Margin
                      -1,981.08
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -15.60
                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Celldex Therapeutics, Inc., was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficu...morelt-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing ...moredrug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology™ program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company’s products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad which include Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Pfizer Inc., and Roche. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as ‘biologics’ under the Public Health Service Act and ‘drugs’ under the Federal Food, Drug and Cosmetic Act.lessless

                      Key People

                      Anthony S. Marucci

                      CEO/Director/President

                      Larry Ellberger

                      Director/Chairman of the Board

                      Avery W. Catlin

                      CFO/Chief Accounting Officer/Secretary/Senior VP

                      Harry H. Penner,Jr

                      Director

                      Karen L. Shoos

                      Director

                      • Celldex Therapeutics Inc

                      • Perryville III Building

                      • Hampton, NJ 08827

                      • USA.Map

                      • Phone: +1 908 200-7500

                      • Fax: +1 908 454-1911

                      • celldex.com

                      Incorporated

                      0

                      Employees

                      129